Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Adjusts PT To $22 (1:14 Reverse Stock Split)
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy, adjusts PT to $22 (1:14 reverse stock split).
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers
Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.
US Markets Turn Higher As Dow Jumps Over 100 Points
U.S. stocks traded higher in volatile trading toward the end of trading, with the Dow Jones gaining more than 100 points on Monday.
Dow, S&P 500 Drop In Volatile Trading Ahead Of Fed’s Rate Decision
U.S. stocks traded lower in volatile trading toward the end of trading, with the Dow Jones dropping around 40 points on Monday.
Why Sonnet BioTherapeutics Shares Are Falling Over 30%
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 36.9% to $1.72 during Monday's trading session after the company announced a 1-for-14 reverse stock split.
What Else?
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday’s Mid-Day Session
Gainers
MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.
US Stocks Turn Higher; Dow Gains Over 80 Points
U.S. stocks turned higher midway through trading, with the Dow Jones gaining more than 80 points on Monday.